Skip to main content
Clinical and Translational Medicine

Table 3 The independent predictive factors for progression-free survival

From: EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Characteristic

HR (95% CI)

P-value

HRa (95% CI)

P-valuea

EGFR plasma after treatment

3.53 (1.38–9.04)

0.008

5.21 (1.38–19.62)

0.014

Brain metastasis after treatment

2.87 (1.21–6.78)

0.016

1.55 (0.52–5.79)

0.512

New metastasis site

2.23 (1.09–4.57)

0.028

1.69 (0.71–4.73)

0.311

  1. a For the newly diagnosed group
Back to article page